The Change And Significance Of Serum Soluble Intercellular Adhesion Molecule-1 Levels In Ankylosing Spondylitis Patients After Treatment With Recombinant Human Tumor Necrosis Factor-Α Receptor Ⅱ IgG Fc Fusion Protein

Objective:To study the changes of soluble intercellular adhesion molecule-1（sICAM-1）levels in active ankylosing spondylitis（AS）patients after recombinant human tumor necrosis factor-αreceptor II IgG Fc fusion protein（rhTNFR-Fc）therapy,and effect of the illness and disease in the AS evaluation.Methods:Twenty-four cases of patients with active AS were treated with rh TNFR-Fc,after 12 weeks patients were randomly divided into A（n=13）,B（n=11）group.A group treated with rhTNFR-Fc and B group treated with traditional drug the next 12 weeks.The levels of sICAM-1 were detected by enzyme-linked immunosorbent assay（ELISA）after treatment.At 0,12^th,24^thweek AS patients got sacroiliac joint MRI scan,gave SPARCC score to each of them.To analyze the change of serum sICAM-1,and the relevance with the clinical indicators by SPSS statistical software.Results:1.The basal serum sICAM-1（ng/ml）level of active AS patients（252.98±86.71）was higher than healthy controls（202.20±60.35）（p<0.05）.2.ESR,CRP,BASDAI,BASF,ASDAS-CRP in 6 weeks,12 weeks,18 weeks（A）,24weeks（A）and ESR,BASDAI,ASDAS-CRP in 18 weeks（B）and BASDAI in 24 weeks（B）were statistically significant,compared to previous points.3.At 6^thh weeks,12 ^thh weeks,18 ^thh weeks（A）,18 ^thh weeks（B）,24 ^thh weeks（A）,24 ^thh weeks（B）the 1evels of sICAM-1 after treatment the level of sICAM-1（ng/ml）respectively were:244.18±77.51,213.42±49.37,219.31±45.70,226.54±58.71,231.54±59.76,236.01±85.05.4.Compare to the previous point,after 12 weeks’treatment the level of sICAM-1 decline significantly（p<0.05）,no statistically significant difference to the rest（p>0.05）.5.Compare group A to B there showed no significant difference（p>0.05）.6.SPARCC score of baseline and12,24weeks（A）,24weeks（B）respectively were 21.04±13.93,10.21±12.61,9.47±9.47,4.09±4.89,there were statistical significances in the comparison to the previous point（p<0.05）.7.Before treatment,only the serum of sICAM-1 positively correlated with CRP and BASFI.8.There was a negative correlation between s ICAM-1and ESR after 6 weeks’treatment and the serum of sICAM-1 at 6^th,12^th,18^th,24^thweek were irrelevant with CRP,BASDAI,BASFI,ASDAS-CRP and SPARCC score.Conclusion:1.The level of sICAM-1 in active AS patients is higher than healthy controls.2.rhTNFR-Fc treatment use to active AS patients can make level of sICAM-1 and SPARCC score decrease.3.The level of sICAM-1 is irrelevant with SPARCC score.4.rhTNFR:Fc can better maintain low disease activity compared to conventional oral medications.